Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.10
$0.10
$0.09
$1.50
$15.86M2.087.28 million shsN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.28
+2.5%
$0.35
$0.23
$2.75
$4.17M0.831.10 million shs1.46 million shs
MAAQ
Mana Capital Acquisition
$1.98
$1.85
$5.35
$10.25
$48.67MN/A33,075 shs41,561 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$2.67
$2.63
$2.33
$4.96
$16.75M0.3830,786 shs246,829 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
0.00%0.00%0.00%+0.00%-70.61%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00%+10.67%-13.96%-52.41%-86.95%
MAAQ
Mana Capital Acquisition
0.00%+1.02%+39.44%-13.54%-46.77%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+8.54%+3.89%+4.30%-22.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$0.10
$0.10
$0.09
$1.50
$15.86M2.087.28 million shsN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$0.28
+2.5%
$0.35
$0.23
$2.75
$4.17M0.831.10 million shs1.46 million shs
MAAQ
Mana Capital Acquisition
$1.98
$1.85
$5.35
$10.25
$48.67MN/A33,075 shs41,561 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$2.67
$2.63
$2.33
$4.96
$16.75M0.3830,786 shs246,829 shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
0.00%0.00%0.00%+0.00%-70.61%
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
0.00%+10.67%-13.96%-52.41%-86.95%
MAAQ
Mana Capital Acquisition
0.00%+1.02%+39.44%-13.54%-46.77%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00%+8.54%+3.89%+4.30%-22.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
1.67
Reduce$1.00870.87% Upside
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1.00
SellN/AN/A
MAAQ
Mana Capital Acquisition
0.00
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest ENSC, MAAQ, APLT, and NAII Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/26/2026
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
Reiterated RatingSell (E+)
4/21/2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
Reiterated RatingSell (E+)
(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
$1M15.86N/AN/A$0.49 per share0.21
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
$5.07M0.84N/AN/A$0.63 per share0.44
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$129.86M0.13N/AN/A$11.07 per share0.24
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
-$105.62M-$0.10N/AN/AN/AN/A-340.84%-175.00%N/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$10.18M-$3.35N/AN/AN/A-250.39%-766.45%-256.59%8/12/2026 (Estimated)
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$13.57M-$2.39N/AN/AN/A-10.13%-12.21%-5.30%N/A

Latest ENSC, MAAQ, APLT, and NAII Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/18/2026Q3 2026
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.72N/A-$0.72N/A$35.48 million
5/15/2026Q1 2026
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$0.73-$0.52+$0.21-$0.52$1.00 million$0.96 million
3/30/2026Q4 2025
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
-$1.26-$0.75+$0.51-$0.75$0.50 million$1.88 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/AN/AN/AN/AN/A
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/AN/AN/AN/AN/A
MAAQ
Mana Capital Acquisition
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
N/A
0.96
0.96
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
N/A
0.71
0.71
MAAQ
Mana Capital Acquisition
N/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.13
1.64
0.87
CompanyEmployeesShares OutstandingFree FloatOptionable
Applied Therapeutics Inc. stock logo
APLT
Applied Therapeutics
30153.96 million151.50 millionOptionable
Ensysce Biosciences, Inc. stock logo
ENSC
Ensysce Biosciences
1015.37 million14.94 millionNot Optionable
MAAQ
Mana Capital Acquisition
18.13 millionN/ANot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.28 million4.97 millionNot Optionable

Recent News About These Companies

Natural Alternatives Resolves Credit Agreement Issues

Media Sentiment Over Time

Applied Therapeutics stock logo

Applied Therapeutics NASDAQ:APLT

$0.10 0.00 (0.00%)
As of 06/18/2026

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Ensysce Biosciences stock logo

Ensysce Biosciences NASDAQ:ENSC

$0.28 +0.01 (+2.47%)
Closing price 06/18/2026 03:58 PM Eastern
Extended Trading
$0.27 0.00 (-1.44%)
As of 06/18/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP oxycodone prodrug candidate for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF614, an extended-release oxycodone-derivative that releases clinically effective oxycodone; PF329 for pain with abuse protection; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD; and PF9001 to treat Opioid use disorder. The company was founded in 2003 and is based in La Jolla, California.

Mana Capital Acquisition NASDAQ:MAAQ

$1.98 0.00 (0.00%)
As of 06/18/2026

Mana Capital Acquisition Corp. focuses on engaging in a merger, stock exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. It intends to focus on businesses operating in the healthcare, technology, green economy, and consumer products sectors in North America, Europe, and Asia. The company was incorporated in 2021 and is based in Dover, Delaware.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$2.67 0.00 (0.00%)
Closing price 06/18/2026 04:00 PM Eastern
Extended Trading
$2.68 +0.01 (+0.37%)
As of 06/18/2026 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.